Immunitas Therapeutics Announces Cell Publication of Tumor Single Cell Analysis Identifying CD161 as a Therapeutic T and NK Cell Target in Immuno-Oncology February 18, 2021
Abveris Announces Antibody Discovery Agreement with Immunitas Using the Berkeley Lights Beacon® October 8, 2020
Jeffrey Goldberg Appointed Chief Executive Officer and Director of Immunitas Therapeutics December 18, 2019
